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PENGARUH POLIMORFISME GEN CYP2D6 DAN DRD2 TERHADAP 
HASILAN KLINIKAL DI KALANGAN PESAKIT SKIZOFRENIA 
 
ABSTRAK 
 
CYP2D6 adalah enzim polimorfik yang terlibat dalam metabolisme pelbagai 
drug yang bertindak di sistem saraf pusat dan sistem kardiovaskular. Gen reseptor 
dopamin D2 (DRD2) pula merupakan calon gen penyebab skizofrenia di samping 
ianyayang boleh mempengaruhi kesan beberapa drug antipsikotik. Polimorfisme gen 
CYP2D6 dan DRD2 dengan itu telah dikaitkan dengan kesan drug antipsikotik di 
kalangan pesakit skizofrenia. Objektif kajian ini adalah untuk membangunkan kaedah 
PCR untuk mengesan polimorfisme gen DRD2 dan untuk mengkaji hubungan 
polimorfisme gen CYP2D6 dan DRD2 dengan kesan rawatan ke atas pesakit 
skizofrenia. Protokol kajian telah mendapat kelulusan Jawatankuasa Kajian dan Etika, 
Universiti Sains Malaysia (USM), Kelantan, Malaysia. Subjek merupakan pesakit 
skizofrenia (DSM-IV) yang dirawat dengan drug antipsikotik atau mempunyai sejarah 
perawatan dengan antipsikotik. Pesakit yang mempunyai diagnosis tambahan lain seperti 
penyalahgunaan dadah atau kecacatan mental tidak dipilih untuk kajian. Penerangan 
yang lengkap tentang kajian diberikan terlebih dahulu kepada pesakit sebelum 
mendapatkan persetujuan mereka secara bertulis. Pesakit kemudianya dipanggil untuk 
satu temuduga dan penilaian lanjut. Tahap keterukan psikopatologikal dinilai 
menggunakan Skala Gejala Positif dan Negatif (PANSS). Kesan sampingan 
ekstrapiramidal pula dinilai melalui Skala Simpson Angus (SAS) manakala kesan 
akatisia ditentukan menggunakan Skala Pengkelasan Akatisia Barnes (BARS). DNA 
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diekstrak daripada darah yang diambil daripada pesakit menggunakan kaedah ‘salting 
out’ dan digunakan untuk ujian PCR. Primer-primer yang spesifik direka bentuk untuk 
membangunkan kaedah PCR untuk mengesan polimorfisme. Kaedah-kaedah yang 
dibangunkan didapati spesifik dan sensitif untuk mengesan genotip CYP2D6 dan DRD2. 
Kaedah ini kemudiannya digunakan untuk menganalisa genotip CYP2D6 dan DRD2 di 
kalangan 156 subjek yang dipilih dan bersetuju untuk menyertai kajian. Untuk CYP2D6, 
frekuensi alel CYP2D6*1, *4, *5, *10 dan gen duplikasi didapati masing-masingnya 
adalah 39.1, 1.3, 3.8, 46.8 dan 3.2% manakala alel CYP2D6*3, *6, *9, *14 dan *17 
tidak dapat dikesan. Untuk gen DRD2 pula, frekuensi alel varian Ser310, Cys311, TaqI 
A1, -141C Del dan -241G adalah masing-masingnya didapati bernilai 0.3, 3.2, 42.3, 14.7 
dan 17.6%. Tiada pesakit diuji positif mempunyai alel varian Ala96, Leu141(T) dan 
Ile154. Terdapat kaitan yang signifikan antara polimorfisme gen CYP2D6 dengan 
markah PANSS subtotal negatif. Pesakit yang mempunyai alel Cys311 pula didapati 
mempunyai markah PANSS yang sangat tinggi berbanding subjek tanpa alel Cys311. 
Penemuan Kkajian ini gagal menunjukkan kaitan polimorfisme gen CYP2D6 dan DRD2 
dengan kesan sampingan terapi antipsikotik dan skor SAS dan BARS di kalangan 
pesakit skizofrenia. Walaubagaimanapun, polimorfisme A-241G didapati mempengaruhi 
pengalaman kesan sampingan penggunaan antipsikotik dalam dua tahun kebelakang. 
Keputusan kajian mencadangkan polimorfisme gen CYP2D6 dan DRD2 mempunyai 
implikasi ke atas tindakbalas rawatan antipsikotik dan kejadian kesan sampingannya. 
Namun demikian, adalah dicadangkan yang kajian lebih besar harus dilakukan untuk 
menilai kesan polimorfisme gen CYP2D6 dan DRD2 sebagai pejangka kesan rawatan 
pesakit skizofrenia. 
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INFLUENCE OF CYP2D6 AND DRD2 POLYMORPHISMS ON CLINICAL 
OUTCOMES OF PATIENTS WITH SCHIZOPHRENIA 
 
ABSTRACT 
 
CYP2D6 is a polymorphic enzyme involved in the metabolism of many centrally 
acting drugs as well as cardiovascular drugs. Dopamine D2 receptor gene (DRD2) is a 
candidate gene implicated in the etiology of schizophrenia and the efficacy of 
antipsychotic drugs. CYP2D6 and DRD2 polymorphisms have been associated with 
antipsychotic drug response in patients with schizophrenia. The objectives of this study 
were to develop PCR methods for detection of DRD2 polymorphisms and to investigate 
the association of the CYP2D6 and DRD2 polymorphisms with treatment outcomes in 
patients with schizophrenia. The protocol for the study was approved by the Research 
and Ethical Committee, Universiti Sains Malaysia (USM), Kelantan, Malaysia. The 
subjects were patients with schizophrenia (DSM-IV) on antipsychotic treatment or had 
been treated with antipsychotic in the past. Patients with co-morbid diagnoses of 
substance abuse or mental retardation were excluded from the study. Written informed 
consent was obtained from the subjects after full explanation of the study procedure. The 
selected patient was then called for interview and further assessment. The 
psychopathological severity was evaluated using the Positive and Negative Symptoms 
Scale (PANSS). The extrapyramidal side-effects and akathisia were assessed with the 
Simpson Angus Scale (SAS) and the Barnes Akathisia Rating Scale (BARS), 
respectively.  DNA was extracted from blood taken from the patients using salting out 
procedures and subjected to PCR-genotyping. Specific primers were designed to develop 
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PCR methods for detection of polymorphisms. The PCR methods were specific and 
sensitive to detect CYP2D6 and DRD2 genotypes. These methods were used for 
genotyping analysis of 156 subjects enrolled in this study for CYP2D6 and DRD2 
polymorphisms. The frequencies for CYP2D6*1, *4, *5, *10 and CYP2D6 duplication 
were 39.1, 1.3, 3.8, 46.8 and 3.2%, respectively; while CYP2D6*3, *6, *9, *14 and *17 
were absent. The frequencies for DRD2 variants Ser310, Cys311, TaqI A1, -141C Del 
and -241G were 0.3, 3.2, 42.3, 14.7 and 17.6%, respectively. There was no patient tested 
positive for Ala96, Leu141(T) and Ile154 variants. We found that CYP2D6 
polymorphism was significantly associated with subtotal negative PANSS score. 
Patients with the Cys311 allele presented with significantly higher PANSS scores than 
those without the Cys311 allele. We also found that CYP2D6 and DRD2 polymorphisms 
were not related to the side-effects of antipsychotic therapy, and the SAS and BARS 
scores.  However, A-241G polymorphism was associated with the experience of side-
effects in the past two years. The results suggested that CYP2D6 and DRD2 
polymorphisms may have implications in the treatment response and the occurrence of 
neuroleptic-induced side-effects. Therefore, CYP2D6 and DRD2 polymorphisms may be 
a predictor for the treatment outcomes of patients with schizophrenia. Further 
investigation is however required to confirm this using a larger sample. 
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CHAPTER 1 
INTRODUCTION AND REVIEW OF LITERATURE 
 
1.1 Introduction 
 
1.1.1 Schizophrenia  
 
Schizophrenia is a major psychotic disorder. The American Psychiatric 
Association’s Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV) describes schizophrenia as a psychiatric disorder characterized by social 
withdrawal and disturbances in thought, motor behavior, and interpersonal functioning 
(American Psychiatric Association, 1994). Schizophrenia can greatly limit the patient’s 
ability to function normally and thus impairs the quality of life. For diagnosis of 
schizophrenia, the DSM-IV is at present perhaps the most widely used, although the 
definition in the 10th edition of the World Health Organization's International 
Classification of Diseases (ICD-10) provides a similar alternative (World Health 
Organization, 1993).  
 
Schizophrenia is a highly heritable condition as demonstrated in family, twin and 
adoption studies (McDonald and Murphy, 2003). Studies have also shown that 
environmental factors combined with genetic predisposition lead to the development of 
schizophrenia (McDonald and Murphy, 2003, Kirov et al., 2005). Identifying genes that 
effect an individual’s predisposition to develop schizophrenia could improve diagnosis 
of the disease, and perhaps lead to improvements in prevention and in pharmacological 
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treatment of the disease. Despite extensive research effort for many years, no mutations 
or disease-predisposing DNA sequence variations have been identified. The mode of 
inheritance of schizophrenia is likely to be polygenic or multifactorial (McDonald and 
Murphy, 2003, Kirov et al., 2005).  
 
1.1.2 Drugs Used in Schizophrenia  
 
The antipsychotic drugs are used very widely to treat the positive symptoms of 
schizophrenia, with some of the newer drugs having effects on negative symptoms, but 
there is still much debate about their precise mechanism of action. They act as dopamine 
antagonists, that is, they block dopamine neurotransmission in limbic and cortical brain 
regions, as these brain regions are considered to be important in mediating the kinds of 
functions that are disturbed in schizophrenia (Strange, 1998). Chlorpromazine and 
haloperidol block dopamine receptors (D2 receptors, in particular) (Strange, 1998, 
Terenius, 2000, Miyamoto, 2005, Krebs et al., 2006). 
 
Antipsychotic drugs are divided into two groups, typical and atypical 
antipsychotics. Typical antipsychotics are defined as drugs that are very effective in 
reducing and controlling positive symptoms but frequently produce side-effects that are 
responsible for a reduced quality of life (Strange, 1998, Miyamoto, 2005, Krebs et al., 
2006). The typical, conventional or first generation antipsychotic includes 
chlorpromazine, haloperidol, fluphenazine, trifluperazine, perphenazine, thioridazine, 
levopromazine, flupenthixol and sulpiride.   
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The atypical drugs are defined as those drugs with therapeutic effects against the 
positive symptoms of schizophrenia but with a reduced tendency to induce motor side-
effects (Strange, 1998, Miyamoto, 2005, Krebs et al., 2006). The atypical or second 
generation antipsychotic includes amisulpride, clozapine, olanzapine, quetiapine, 
risperidone, sertindole, zotepine and aripiprazole. 
 
Pharmacological treatment of schizophrenia involves antipsychotic therapy. The 
variation in individual clinical response to antipsychotic therapy remains a critical 
problem in the management of patients with schizophrenia despite considerable progress 
has been made in delineating different domains of this illness, ranging from positive and 
negative symptoms to cognitive dysfunction and psychosocial vulnerabilities. Although 
a minority of patients may experience complete symptom remission, a large proportion 
of patients continues to experience significant psychiatric symptoms (Kane, 1999, Hariri 
and Lewis, 2006). In addition there is a subset of patients who develop drug-induced 
side-effects such as extrapyramidal side-effects include acute dystonic reactions, 
neuroleptic-induced parkinsonism and akathisia, later-onset movement disorders such as 
tardive dyskinesia or dystonia, and life threatening side-effects for example 
agranulocytosis and neuroleptic malignant syndrome that require significant medical 
intervention (Krebs et al., 2006). Genetic factors may be considered as one of the cause 
of this phenomenon. Psychopharmacogenetic studies have focused on three major 
phenotypes that are clinical efficacy of antipsychotic drugs, efficacy of antidepressant 
medications, and development of side-effects associated with the treatment (Malhotra et 
al., 2004). 
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1.1.3  CYP2D6 Enzyme 
 
The cytochromes P450 (CYPs) are a multi-gene family of constitutive and 
inducible heme-containing monooxygenases that play a major role in the oxidative 
metabolism of a wide range of environmental chemicals including carcinogens and 
toxins as well as therapeutic drugs (Omura, 1999). They are predominately expressed in 
the liver, but they are also expressed in the extrahepatic tissues including gut, kidney, 
lung, skin and brain (Ingelman-Sundberg et al., 1999, Zanger et al., 2004, Miksys et al., 
2005).  
 
Two percent of CYP enzymes in the human liver consist of CYP2D6. CYP2D6 
or debrisoquine 4-hydroxlase is the most extensively studied enzyme compared to other 
CYP enzymes. CYP2D6 is involved in the metabolism of several neuroleptics, tricyclic 
antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) (Linder et 
al., 1997, Ingelman-Sundberg et al., 1999, Gardiner and Begg, 2006). Its activity 
exhibits genetic polymorphism, meaning that distinct population differences are 
apparent in its expression or activity.  
 
Table 1.1 shows drug substrates and inhibitors for CYP2D6 enzyme. A drug that 
is metabolized through CYP2D6 enzyme is referred to as a substrate of the enzyme. 
Increased CYP2D6 enzyme activity results in faster metabolism and a shorter-than-
expected half-life with potential loss of pharmacologic effect over time. In contrast, 
CYP2D6 enzyme inhibition may occur, resulting in a significant increase in circulating 
plasma concentration of a drug being metabolized by the enzyme. Consequently, the 
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potential for increased side-effect or toxicity may occur at standard dosing regimens 
(Gardiner and Begg, 2006).  
 
Table 1.1  Drug Substrates and Inhibitors for CYP2D6 Enzyme 
 
Substrates  Inhibitors 
 
Antidepressant:  
Amitriptyline, Citalopram, 
Clomipramine, 
Desipramine, Doxepin, 
Fluvoxamine, Imipramine, 
Maprotiline, Mianserin, 
Nortriptyline,  Venlafaxine, 
Fluoxetine, Paroxetine, 
Trazodone, Mirtazapine, 
Sertraline, Bupropion 
 
 
Beta blockers:  
Carvedilol, Yohimbine, 
Propranolol, Metoprolol, 
Timolol, Bufuralol, 
Alprenolol, Labetolol, 
Pindolol, Oxprenolol  
 
Opioid analgesics: 
Codeine, Dihydrocodeine, 
Morphine, Tramadol 
 
 
Antidepressant:  
Clomipramine, 
Desipramine, 
Amitriptyline, Fluoxetine, 
Fluvoxamine, Paroxetine, 
Sertraline, Citalopram, 
Nefazodone, Bupropion, 
Duloxetine, Moclobemide 
 
Antipsychotics:   
Fluphenazine, Thioridazine, 
Risperidone, Perphenazine, 
Haloperidol, Clozapine, 
Chlorpromazine, 
Olanzapine, Zuclopenthixol, 
Trifluperidol,  
Aripiprazole 
 
Antiarrhythmics: 
Flecainide, Mexiletine, 
Propafenone, Encinide, 
Perhexiline, N-
Propylajmaline, Quinidine, 
Amiodarone 
 
 
 
Anticancer agents: 
Debrisoquine, Gefitinib, 
Sparteine, Tamoxifen 
 
 
 
Other:  
Atomoxetine, 
Dextromethorphan, 
Perhexilline, Tolterodine, 
Nicotine, Omeprazole 
 
Antipsychotics:  
Chlorpromazine, 
Thioridazine, Haloperidol, 
Perphenazine, 
Fluphenazine 
 
 
Beta blockers: 
Propranolol 
 
 
Other:  
Quinidine, Cimetidine 
 
Data compiled from Masimirembwa and Hasler (1997), Linder et al. (1997), Cupp and Tracy 
(1998), Ingelman-Sundberg et al. (1999), Bertilsson et al. (2002), Ingelman-Sundberg (2005), 
Gardiner and Begg (2006), Bondy and Spellmann (2007) and Vandel et al. (2007). Substrates 
are expected to be influenced by CYP2D6 polymorphisms and inhibitors are expected to 
influence other substrates of CYP2D6 if they are co-prescribed. 
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1.1.4  CYP2D6 Gene  
 
The protein responsible for the altered metabolism of debrisoquine and sparteine 
was purified from human liver microsomes by Distlerath et al. (1985). Gonzalez et al. 
(1988a) isolated a full-length human cDNA that was shown to encode a distinct, novel 
member of the CYP2D subfamily, which was renamed CYP2D6. In order to determine 
on which chromosome the gene controlling human cytochrome P450 
(debrisoquine/sparteine type) is located a linkage study of polymorphic sparteine 
oxidation (PSO) to various polymorphic markers was carried out (Eichelbaum et al., 
1987).  They found that the gene controlling human cytochrome P450 
(debrisoquine/sparteine) is situated on the long arm of chromosome 22 and the CYP2D 
locus (22q 13.1) was also subsequently mapped by using the CYP2D6 cDNA 
(Eichelbaum et al., 1987, Gonzalez et al., 1988b).  
 
In humans, the CYP2D6 wild-type locus contains three highly homologous 
genes, CYP2D8P, CYP2D7P, and CYP2D6 located in 5’- to 3’-orientation on a 
contiguous region of about 45 kb (Kimura et al., 1989). The CYP2D genes consist of 
nine exons and eight introns (Figure 1.1). The CYP2D8P is a pseudogene and contains 
multiple deletions and insertions and causes a highly disrupted open reading frame. The 
CYP2D7P gene resembles CYP2D6 more than it does CYP2D8P. Its coding sequence 
indicates only a single inactivating mutation, an insertion of T226 in the first exon. No 
specific mRNA product has however been detected in the RNA from human livers 
suggesting that it also is a pseudogene (Kimura et al., 1989).   
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Figure 1.1 A Region from Exon 1 to 9 of the CYP2D6 Gene 
 
Human CYP2D gene cluster consist of CYP2D8P, CYP2D7 and CYP2D6. Moreover, CYP2D6 contains nine exons and eight introns with 
specific mutations or polymorphisms on them. There are seven alleles screened (CYP2D6*3, *4, *6, *9, *10, *14 and *17) using allele-
specific multiplex polymerase chain reaction (PCR). 
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1.1.5  CYP2D6 Polymorphisms 
 
The gene encoding CYP2D6 is highly polymorphic. CYP2D6 allele 
nomenclature is available at http://www.cypalleles.ki.se/cyp2d6.htm. Currently, more 
than 50 mutations and 90 alleles for CYP2D6 have been discovered, with many of these 
leading to the poor-metabolizer phenotype (Ingelman-Sundberg et al., 2000, Miksys et 
al., 2005). Many different polymorphisms have been reported in all parts of the world 
that affected CYP2D6 activity (Sistonen et al., 2007). Studies showed that genetic 
polymorphism of the drug metabolizing enzymes may contribute to inter-individual 
variations in plasma levels of antipsychotics (Jaanson et al., 2002, Bertilsson et al., 
2002, Ozdemir et al., 2007). Patients with genetically determined poor metabolizers 
(PMs) status might require lower doses of antipsychotics (Vandel et al., 2007). 
Alternatively, ultrarapid metabolizers (UMs) will need increased drug dosage to obtain 
therapeutic response (Scordo et al., 1999, Vandel et al., 2007). There are fewer data on 
the impact of CYP2D6 polymorphism on therapeutic efficacy (Brockmöller et al., 2002), 
especially in long-term treatment (Hamelin et al., 1999, Malhotra et al., 2004). 
 
The CYP2D6 allele subgroups are associated with absent, decreased, normal or 
increased enzyme activity (Cai et al., 2006). An individual's highest functioning 
CYP2D6 allele predicts his/her phenotypic activity (for example extensive metabolizer 
(EM) allele and PM allele results in an EM phenotype, UM allele and EM allele results 
in UM phenotype, intermediate metabolizer (IM) allele and PM allele results in IM 
phenotype) (Zanger et al., 2004, Gardiner and Begg, 2006).  
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These mutations include genetic alterations that lead to over expression (gene 
duplication), absence of an active protein product (null allele), or production of a mutant 
protein with diminished catalytic capacity (inactivating allele). Patients who express 
dysfunctional or inactive enzyme molecules are considered PMs. The molecular genetic 
basis for the PM status has been shown to be the occurrence of combinations of any of a 
number of null allele. So, a carrier of two null alleles is considered a PM (Linder et al., 
1997, Sachse et al., 1997, Zanger et al., 2004, Gardiner and Begg, 2006). At least 15 null 
alleles encoding non-functional gene including CYP2D6*3, *4, *5, *6 and *14 have 
been reported.  
 
In addition to null alleles, there are also alleles that cause diminished or altered 
drug metabolism leading to the production of a low activity enzyme but not resulting in 
the PM status. So, a carrier of two reduced function or one reduced and one non-
functional allele is considered an IM, while a carrier of only one defective allele and one 
fully functional CYP2D6 allele is considered an EM phenotype (Zanger et al., 2001, 
Gardiner and Begg, 2006).  
 
Extensive metabolizers are patients who express enzymes that have normal 
(extensive) activity, in whom the anticipated medication response would be seen with 
standard doses of drugs. A subject homozygous for the wild-type allele, CYP2D6*1 is 
considered as EM phenotype. Among the EMs metabolic rate can range considerably. In 
subjects homozygous for the active alleles, CYP2D6 drugs are metabolized more 
efficiently than the heterozygous genotypes (one active and one defective allele). In 
general, the drug metabolism phenotype is determined by the number of functional  
Formatted: Normal + Justified;First
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CYP2D6 gene present (Johansson et al., 1993, Sachse et al., 1997, Zanger et al., 2001). 
At the opposite side of the spectrum of EMs, the UM phenotype is consequent to a gene 
duplication (possess multiple functional copies of a single CYP2D6 gene).  
 
Details on nucleotide changes of CYP2D6 alleles and their structural effects are 
shown in Table 1.2 and CYP2D6 alleles frequencies in patients with schizophrenia are 
shown in Table 1.3. 
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Table 1.2  Functional Nucleotide Changes and Structural Effects of 
CYP2D6 Alleles  
 
CYP2D6 
activity 
Functional nucleotide 
changes 
Structural effects References  
    
Normal:    
   CYP2D6*1 
   (Wild-type) 
None  None Zanger et al. (2004) 
    
Increased:     
  CYP2D6*1XN  
 
CYP2D6 duplication N active genes Zanger et al. (2004) 
Decreased:    
   CYP2D6*9 AGA 2613-2615 
deletion 
K281 deletion Zanger et al. (2004) 
   CYP2D6*10 C100T Amino acid change 
P34S and S486T 
 
Zanger et al. (2004) 
   CYP2D6*17 C1023T, C2850T  Amino acid change 
T107I, R296C and 
S486T 
Zanger et al. (2004) 
Absent:    
CYP2D6*3  A2549 deletion in 
exon 5 
Frameshift Zanger et al. (2004) 
CYP2D6*4 G1846A Splice site defect Zanger et al. (2004) 
CYP2D6*5 CYP2D6 deletion Gene absence Zanger et al. (2004) 
CYP2D6*6 T1707 deletion in 
exon 3 
Frameshift Zanger et al. (2004) 
CYP2D6*14 G1758A Amino acid change 
P34S, G169R, 
R296C and S486T 
 
Zanger et al. (2004) 
 
Nucleotide variations in bold are the major SNPs/alterations responsible for the phenotype of the 
corresponding allele. Individuals carrying two null alleles (CYP2D6*3, *4, *5, *6 and *14) are 
PMs, while those carrying two alleles conferring decreased enzyme activity (CYP2D6*9, *10 
and *17), or one null allele and one decreased allele are IMs and those with one or two 
functional alleles (CYP2D6*1) are EMs. Subjects with duplicated gene are classified as UMs. 
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Table 1.3  CYP2D6 Alleles Frequencies in Patients with Schizophrenia 
 
CYP2D6*3    
References  Ethnicity Number of subject, 
N 
Frequency 
(%) 
Ohmori et al. (1998) Japanese 100 0.0 
Suzuki et al. (1998) Japanese 62 0.0 
Nikoloff et al. (2002) Korean 202 0.0 
Andreassen et al. (1997) Scottish  100 0.5 
Kapitany et al. (1998) Austrians 45 0.0 
Hamelin et al. (1999) Caucasian 89  3.9 
Scordo et al. (1999) Italians 37 0.0 
Aitchison et al. (1999) Britains 235 1.7 
Scordo et al. (2000) Italians 119 0.4 
Topić et al. (2000) Caucasian 86 0.0 
Jaanson et al. (2002) Estonian/Russians 52 3.8 
Plesničar et al. (2006) Slovenians 131 3.4 
Llerena et al. (2007) Caucasian 128 0.0 
 
CYP2D6*4    
Ohmori et al. (1998) Japanese 100 0.5 
Suzuki et al. (1998) Japanese 62 0.0 
Kato et al. (2007) Japanese 53 0.9 
Nikoloff et al. (2002) Korean 202 0.0 
Andreassen et al. (1997) Scottish  100 18.0 
Kapitany et al. (1998) Austrians 45 17.8 
Hamelin et al. (1999) Caucasian 89  16.9 
Scordo et al. (1999) Italians 37 23.0 
Aitchison et al. (1999) Britains 235 22.3 
Scordo et al. (2000) Italians 119 17.2 
Topić et al. (2000) Caucasian 86 24.0 
Jaanson et al. (2002) Estonian/Russians 52 16.4 
Riedel et al. (2005) Germans 59 6.8 
Plesničar et al. (2006) Slovenians 131 17.9 
Llerena et al. (2007) Caucasian 128 20.3 
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Table 1.3 ……Continued 
 
CYP2D6*5    
References  Ethnicity Number of subject, 
N 
Frequency 
(%) 
Suzuki et al. (1998) Japanese 62 5.7 
Someya et al. (1999) Japanese 47 4.3 
Suzuki et al. (2001d) Japanese 43 4.7 
Kato et al. (2007) Japanese 53 10.4 
Roh et al. (2001a) Korean  120 1.7 
Nikoloff et al. (2002) Korean 202 2.7 
Andreassen et al. (1997) Scottish  100 4.0 
Kapitany et al. (1998) Austrians 45 2.2 
Hamelin et al. (1999) Caucasian 89  3.9 
Scordo et al. (1999) Italians 37 5.4 
Aitchison et al. (1999) Britains 235 2.3 
Scordo et al. (2000) Italians 119 2.9 
Topić et al. (2000) Caucasian 86 0.0 
Plesničar et al. (2006) Slovenians 131 2.3 
Llerena et al. (2007) Caucasian 128 1.6 
 
CYP2D6*6    
Nikoloff et al. (2002) Korean 202 0.0 
Andreassen et al. (1997) Scottish  100 2.0 
Hamelin et al. (1999) Caucasian 89  0.0 
Scordo et al. (1999) Italians 37 0.0 
Scordo et al. (2000) Italians 119 1.3 
Topić et al. (2000) Caucasian 86 2.1 
Riedel et al. (2005) Germans 59 0.0 
Plesničar et al. (2006) Slovenians 131 2.3 
Llerena et al. (2007) Caucasian 128 7.4 
 
CYP2D6*9    
Ohmori et al. (1998) Japanese 100 0.0 
Nikoloff et al. (2002) Korean 202 0.0 
Plesničar et al. (2006) Slovenians 131 1.5 
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Table 1.3 ……Continued 
 
CYP2D6*10    
References  Ethnicity Number of subject, 
N 
Frequency 
(%) 
Ohmori et al. (1998) Japanese 100 51.5 
Suzuki et al. (1998) Japanese 62 25.0 
Mihara et al. (1999) Japanese 67 29.9 
Someya et al. (1999) Japanese 47 31.9 
Suzuki et al. (2001d) Japanese 43 36.1 
Kato et al. (2007) Japanese 53 31.1 
Roh et al. (2001a) Korean  120 53.8 
Roh et al. (2001b) Korean 82 53.1 
Nikoloff et al. (2002) Korean 202 46.8 
Plesničar et al. (2006) Slovenians 131 4.2 
Llerena et al. (2007) Caucasian 128 2.3 
 
CYP2D6*14    
Nikoloff et al. (2002) Korean 202 0.3 
Riedel et al. (2005) Germans 59 0.0 
Plesničar et al. (2006) Slovenians 131 0.0 
 
CYP2D6*17    
Llerena et al. (2007) Caucasian 128 0.0 
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1.1.6  Dopaminergic Pathway 
 
There are four major pathways where the neurotransmitter dopamine is involved 
and they include the mesolimbic, mesocortical, nigrostriatal and tuberoinfundibular 
pathways. The mesolimbic pathway links the ventral tegmentum area in the midbrain to 
the nucleus accumbens in the limbic system. It is one of the major pathways targeted by 
antipsychotic medication. Although poorly understood, disruption to dopamine function 
(particularly, an excess of dopamine) in this area has been linked to psychosis and the 
positive symptoms of schizophrenia (particularly delusions and hallucinations). 
Successful antipsychotic medication is therefore thought to have its effect by blocking 
dopamine receptors in this pathway. 
 
The mesocortical pathway connects the ventral tegmentum to the cortex, 
particularly the frontal lobes. This pathway is thought to be associated with the negative 
symptoms of schizophrenia, which include avolition, alogia and flat affect (lack of 
emotional response). 
 
The nigrostriatal pathway connects the substantia nigra with the striatum. It is 
particularly involved in the production of movement, as part of a system called the basal 
ganglia motor loop. Loss of dopamine neurons in the substantia nigra is one of the main 
pathological features of PD, leading to a marked reduction in dopamine function in this 
pathway. This pathway is also implicated in producing TD, one of the side-effects of 
antipsychotic drugs. This medication (particularly the older typical antipsychotics) 
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blocks DRD2 receptors in multiple pathways in the brain. When this happens in the 
nigrostriatal pathway, similar movement problems to those found in PD can occur. 
 
The tuberoinfundibular pathway runs between the hypothalamus and the pituitary 
gland. Some antipsychotic drugs block dopamine in the tuberoinfundibular pathway 
which can cause an increase in blood prolactin levels, leading in some cases to 
hyperprolactinemia.  
 
1.1.7  Dopamine D2 Receptor Gene (DRD2) 
 
Receptor cloning has identified two isoforms of the DRD2 receptors (D2short 
and D2long).  The difference between D2short and D2long is a 29 amino acid residues 
located in the putative third cytoplasmic loop of the receptor protein coded by an exon 
that is missing in D2short (Grandy et al., 1989b).  
 
The DRD2 gene is mapped to chromosome 11 q22-23 (Grandy et al., 1989b). 
The DRD2 has 443 amino acids, 33 654 bp’s and has molecular weight of 50 619 Da. It 
has eight exons that spans approximately 270 kb and includes an intron of approximately 
250 kb separating the first exon from the exons encoding the receptor protein.  
 
Protein coding regions are absent in exon 1 and present in exons 2 to 8 (Grandy 
et al., 1989b). Exons 2 to 8 (which were amplified in most current studies for example in 
the study by Gejman et al. (1994) correspond to exons 1 to 7 of a previous nomenclature 
(Grandy et al., 1989b).  Exons 2 to 8 span 14 kb (Figure 1.2).   
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Figure 1.2  Dopamine D2 Receptor Gene Structure and Polymorphisms Studied. 
 
Boxes represent exons; horizontal lines connecting boxes represent introns, promoter and 
untranslated regions; arrows indicate relative locations of the polymorphisms. 
 
1.1.8  DRD2 Polymorphisms 
 
Gejman et al. (1994) detected three variants that predict amino acid substitutions 
in DRD2.  In exon 3, a substitution of alanine for valine was found at codon 96, which 
corresponds to the extracellular portion of the second transmembrane domain and 
therefore might be expected to affect the ligand binding pocket of the DRD2 receptor, 
since residues in the second and other transmembrane domains have been shown to 
regulate ligand binding.  
 
Two non-silent DNA variants were found in exon 7. Substitution of serine for 
proline at codon 310 and cysteine for serine at codon 311 are located in the putative 
third cytoplasmic loop of the human DRD2 and might be expected to affect the 
interaction with G-proteins, and therefore signal transduction, as studies with mutated G-
Val96Ala Ser311Cys Val154Ile 
-141C  
Ins/Del 
A-241G 
TaqI A 
Leu141Leu Pro310Ser 
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protein coupled receptors have shown that this domain is a major determinant of G-
protein coupling.   
 
Arinami et al. (1997) reported two polymorphisms in the 5’-flanking region of 
the human DRD2 gene: a rare adenosine to guanine transversion at position -241 (A-
241G) and a single base pair cytosine insertion/deletion polymorphism at position -141 
(-141C Ins/Del) in which the extra base (-141 Ins) creates a BstNI restriction site.  
 
TaqI A polymorphism or TaqI A Restriction Fragment Length Polymorphism 
(RFLP) is a single nucleotide polymorphism (SNP) altering a TaqI restriction site, 
creating the A1 and A2 alleles (Grandy et al., 1989a, Hauge et al., 1991). This 
polymorphism is not located in the coding region of the gene. It is located at 10 541 kb 
downstream of DRD2 stop codon (exon 8).  
 
Details on characteristic and position of DRD2 polymorphisms are shown in 
Table 1.4 and DRD2 alleles frequencies in patients with schizophrenia are shown in 
Table 1.5. 
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Table 1.4  Characteristics and Positions of DRD2 Polymorphisms  
 
Polymorphism  Characteristic mutation (s) Position Acession no. 
    
Val96Ala Substitution of alanine for valine at 
codon 96 
14858 AF050737 
Leu141Leu Silent substitution at codon 141 
(C→T) 
16019 AF050737 
 
Val154Ile Substitution of isoleucine for valine at 
codon 154  
16058 AF050737 
Pro310Ser Substitution of serine for proline at 
codon 310  
20225 AF050737 
Ser311Cys Substitution of cysteine for serine at 
codon 311 
20229 AF050737 
TaqI A Alteration of a TaqI restriction site at 
10541 kb downstream of DRD2 stop 
codon (exon 8) 
32806 
 
AF050737 
A-241G Substitution of Guanine for Adenosine 
at -241  
6091 AF148806 
-141C Ins/Del Single base pair cytosine insertion/ 
deletion at position -141  
6191 AF148806 
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Table 1.5  DRD2 Alleles Frequencies in Patients with Schizophrenia 
 
TaqI A1 allele    
References  Ethnicity Number of subject, 
N 
Frequency 
(%) 
Suzuki et al. (2000a) Japanese 61 36.1 
Hori et al. (2001b) Japanese 198 60.9 
Suzuki et al. (2001c) Japanese 138 35.1 
Dubertret et al. (2001) French Caucasian 50 15.0 
Kaiser et al. (2002) German Caucasian 665 16.9 
Dubertret et al. (2004) French Caucasian 103 17.0 
Chen et al. (1997) Taiwanese  177 40.7 
-141C Del allele    
Arinami et al. (1997) Japanese 260 14.2 
Ohara et al. (1998) Japanese 170 10.0 
Inada et al. (1999) Japanese 234 17.9 
Hori et al. (2001a) Japanese 201 18.2 
Mihara et al. (2001a) Japanese 52 13.5 
Suzuki et al. (2001a) Japanese 49 14.3 
Hori et al. (2001b) Japanese 200 19.5 
Himei et al. (2002) Japanese 190 19.7 
Stöber et al. (1998) German Caucasian 260 10.8 
Li et al. (1998) European Caucasian 145 13.4 
Jönsson et al. (1999b) Swedish Caucasian 129 5.8 
Tallerico et al. (1999) North American  50 10.0 
Kaiser et al. (2002) German Caucasian 665 9.1 
Kampman et al. (2003) Finnish Caucasian 93 3.8 
Dubertret et al. (2004) French Caucasian 103 10.2 
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Table 1.5 ……Continued  
 
Cys311 allele    
References  Ethnicity Number of subject, 
N 
Frequency 
(%) 
Arinami et al. (1994) Japanese 156 5.4 
Nanko et al. (1994) Japanese 100 3.5 
Tanaka et al. (1996) Japanese 106 4.2 
Harano (1997) Japanese 70 5.7 
Fujiwara et al. (1997) Japanese 52 1.9 
Hori et al. (2001a) Japanese 201 5.0 
Hori et al. (2001b) Japanese 200 1.5 
Himei et al. (2002) Japanese 190 3.9 
Gejman et al. (1994) Caucasian 106 1.4 
Asherson et al. (1994) European Caucasian 112 0.9 
Shaikh et al. (1994) European Caucasian 147 2.4 
Nöthen et al. (1994) German Caucasian 179 1.1 
Crawford et al. (1996) American  84 4.2 
Sasaki et al. (1996) European Caucasian 273 2.2 
Verga et al. 1997 Italian Caucasian 103 5.3 
Serretti et al. (2000) Italian Caucasian 366 5.1 
Kaiser et al. (2002) German Caucasian 665 2.3 
Dubertret et al. (2004) French Caucasian 103 2.9 
Chen et al. (1996) Taiwanese 114 1.8 
 
Leu141 (T) allele    
Kaiser et al. (2002) German Caucasian 665 2.3 
 
Ser310 allele    
Kaiser et al. (2002) German Caucasian 665 0.3 
Gejman et al. (1994) Caucasian 106 0.0 
 
-241G allele    
Kaiser et al. (2002) German Caucasian 665 5.5 
Arinami et al. (1997)  229 10.0 
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1.2 Literature Review 
 
1.2.1 Genetic Polymorphism Analysis of DRD2 by Polymerase Chain Reaction 
 
Single nucleotide polymorphisms (SNPs) analysis for characterizing known 
mutations can be performed by DNA polymerase extension (pyrosequencing and 
microarray primer extension), allele specific oligonucleotides, ASOs (oligonucleotide 
ligation, allele specific PCR, hybridization and cleavage) and restriction site analysis 
(restriction fragment length polymorphism, RFLP and cleaved amplified polymorphic 
sequences, CAPS). Characterization of unknown mutations can be performed by direct 
sequencing, single stranded conformational polymorphism (SSCP), denaturing high 
performance liquid chromatography (DHPLC) and enzymatic mismatch detection.  
 
Several methods are available for characterizing known mutations of DRD2 gene 
such as polymerase chain reaction–restriction fragment length polymorphism (PCR–
RFLP) (Hauge et al., 1991, Itokawa et al., 1993, Arinami et al., 1994, Gejman et al., 
1994, Arinami et al., 1997, Hori et al., 2001a), denaturing gradient gel electrophoresis 
(DGGE) (Gejman et al., 1994), Southern blot analysis (Grandy et al., 1989a, Grandy et 
al., 1989b, Hauge et al., 1991) and also direct sequencing (Grandy et al., 1989a, Grandy 
et al., 1989b, Hauge et al., 1991). Although useful, these methods may not be suitable 
for population studies because they are generally costly, tedious and may require 
expensive instrumentation and manpower. A new method for the simultaneous detection 
of DRD2 polymorphisms that is simpler, less costly and maintaining sensitivity would 
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therefore be timely. Applications of this method will enable population studies to be 
conducted in a larger scale by less specialized personnel in normal laboratory settings. 
 
There are two big issues in order to identify and detect a specific sequence in a 
genome. Firstly, there are many sequences in a genome that we are not interested in 
detecting (specificity). Secondly, the amount of DNA in samples that we are interested 
with, is very small (amplification). However, polymerase chain reaction (PCR) solves 
both of these issues by specifically amplify defined segments of genomic DNA.  
 
Components of PCR reaction are buffer, magnesium, dNTPs (free nucleotides in 
order to extend the primer with), a DNA template and polymerase. Polymerase chain 
reaction happens in three steps such as denaturation, annealing and extension. The 
temperature alternations in these three steps are controlled by a thermal cycler.  
 
Denaturation is the step in which the DNA strands are separated by the melting 
of the bonds between base pairs. Annealing is stage at which the attachment of a primer 
happens. A primer is about 18 to 30 base pairs of DNA that is specific to the interested 
regions of a gene or sequence. The temperature is changed to the optimum temperature 
in order for the DNA polymerase to catalyse extension of the primers, i.e. to copy the 
DNA between the primers. This reaction mix is repeatedly heated and cooled a total of 
25 to 35 times to produce a greater than million-fold amplification of the target DNA. 
 
Two common ways are used to characterize PCR products such as agarose gels 
and polyacrylamide gels. Agarose gels are horizontal, while polyacrylamide gels are 
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vertical. DNA samples are loaded somewhat similarly in that they are loaded into 
separate lanes that are made at the top of the gel. Gel electrophoresis works on the 
principle that DNA is negatively charged. By having a positive charge at one end of the 
gel and having a negative charge at the other (where the DNA samples are loaded into 
the gel), the samples will thus be “attracted” to the positive end when electricity is run 
through the gel. Some people are homozygous for a particular allele while others are 
heterozygous. Thus, the DNA fragments that have been amplified using PCR will be 
different in size. Since smaller sized fragments have an easier time migrating through 
the pores in the gel, they will travel farther along than larger sized fragments. Therefore, 
individual variation for a particular allele can be studied.  
 
1.2.2  Association of the CYP2D6 Polymorphisms with Schizophrenia 
 
The group of patients with schizophrenia from Germany studied by Topić et al. 
(2000) showed a significant difference in the allele prevalence (p = 0.002), genotype 
distribution (p = 0.016) and predicted phenotype (p = 0.018) from the control group. 
Results of the study by Llerena et al. (2007) also supported the hypothesis of a potential 
role of CYP2D6 in the vulnerability to schizophrenia.  
 
Armstrong et al. (1997) found a slightly increased incidence of the PMs (6.6%) 
among patients with schizophrenia compared to healthy volunteers (4.5%) from 
European Caucasian origin, but the difference was not significant. Result from a study 
by Hamelin et al. (1999) among French Canadian origin contradicted that of Armstrong 
et al. (1997), where they found a lower incidence of the PMs (6.7%) among patients 
